Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for ...

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data

Connecticut-based Braidwell disclosed a sale of 1,779,953 shares of Xenon Pharmaceuticals(NASDAQ:XENE) in its February 17, 2026, SEC filing, an estimated $74.76 million trade based on quarterly ...
Nasdaq

Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b "X-TOLE" Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy ...

The webcast will be broadcast live on the Investors section of the Xenon website, and participants will be able to submit text questions via the webcast portal. The webinar will also be available for ...
WNCT

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 ...

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting ...
Seeking Alpha

Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity

Xenon Pharmaceuticals appears undervalued heading into a pivotal phase two MDD trial readout due by the end of November. If XEN-1101 shows either a trend towards improvement or hits the primary ...
Nasdaq

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the ...
Yahoo Finance

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data

Connecticut-based Braidwell disclosed a sale of 1,779,953 shares of Xenon Pharmaceuticals (NASDAQ:XENE) in its February 17, 2026, SEC filing, an estimated $74.76 million trade based on quarterly ...